New Zealand markets closed

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.74+0.08 (+1.20%)
At close: 04:00PM EDT
6.61 -0.13 (-1.93%)
After hours: 04:07PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 28.44M
Enterprise value 15.60M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.99
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.36

Trading information

Stock price history

Beta (5Y monthly) 2.29
52-week change 333.73%
S&P500 52-week change 316.57%
52-week high 313.17
52-week low 32.11
50-day moving average 36.71
200-day moving average 36.55

Share statistics

Avg vol (3-month) 311.53k
Avg vol (10-day) 38.27k
Shares outstanding 54.42M
Implied shares outstanding 64.42M
Float 84.41M
% held by insiders 10.31%
% held by institutions 117.76%
Shares short (14 Sept 2023) 465.37k
Short ratio (14 Sept 2023) 46.45
Short % of float (14 Sept 2023) 41.48%
Short % of shares outstanding (14 Sept 2023) 41.48%
Shares short (prior month 14 Aug 2023) 480.26k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:30
Last split date 313 Feb 2023

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Jun 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-44.19%
Return on equity (ttm)-156.60%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)-16.14M
EBITDA -43.75M
Net income avi to common (ttm)-46.19M
Diluted EPS (ttm)-10.38
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)36.57M
Total cash per share (mrq)8.27
Total debt (mrq)23.72M
Total debt/equity (mrq)249.14%
Current ratio (mrq)2.34
Book value per share (mrq)2.15

Cash flow statement

Operating cash flow (ttm)-37.62M
Levered free cash flow (ttm)-21.98M